Literature DB >> 16288006

Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells.

Jingjing Chai1, Aubri L Charboneau, Bryan L Betz, Bernard E Weissman.   

Abstract

hSNF5, the smallest member of the SWI/SNF chromatin remodeling complex, is lost in most malignant rhabdoid tumors (MRT). In MRT cell lines, reexpression of hSNF5 induces G1 cell cycle arrest, elevated p16INK4a, and activated replicative senescence markers, such as beta-galactosidase (beta-Gal) and plasminogen activator inhibitor-1. To compare the replicative senescence caused by hSNF5 in A204 cells to normal cellular senescence, we examined the activation of both p16INK4a and p21CIP/WAF1. Analogous to normal cellular senescence, both p16INK4a and p21CIP/WAF1 were up-regulated following hSNF5 restoration. Furthermore, we found that hSNF5 bound the p16INK4a and p21CIP/WAF1 promoters, suggesting that it directly regulates transcription of these genes. Using p16INK4a RNA interference, we showed its requirement for the replicative senescence caused by hSNF5 but not the growth arrest. Instead, p21CIP/WAF1 remained activated by hSNF5 in the absence of high p16INK4a expression, apparently causing the growth arrest in A204. Interestingly, we also found that, in the absence of p16INK4a, reexpression of hSNF5 also increased protein levels of a second cyclin-dependent kinase (CDK) inhibitor, p18INK4c. However, our data show that lack of hSNF5 does not abrogate cellular responsiveness to DNA damage or growth-inhibitory factors. In summary, our studies suggest that hSNF5 loss may influence the regulation of multiple CDK inhibitors involved in replicative senescence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288006     DOI: 10.1158/0008-5472.CAN-05-1896

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

2.  Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Authors:  Zainab Jagani; E Lorena Mora-Blanco; Courtney G Sansam; Elizabeth S McKenna; Boris Wilson; Dongshu Chen; Justin Klekota; Pablo Tamayo; Phuong T L Nguyen; Michael Tolstorukov; Peter J Park; Yoon-Jae Cho; Kathy Hsiao; Silvia Buonamici; Scott L Pomeroy; Jill P Mesirov; Heinz Ruffner; Tewis Bouwmeester; Sarah J Luchansky; Joshua Murtie; Joseph F Kelleher; Markus Warmuth; William R Sellers; Charles W M Roberts; Marion Dorsch
Journal:  Nat Med       Date:  2010-11-14       Impact factor: 53.440

Review 3.  Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.

Authors:  Kimberly H Kim; Charles W M Roberts
Journal:  Cancer Genet       Date:  2014-04-13

Review 4.  ATP-dependent chromatin remodelers in ageing and age-related disorders.

Authors:  Pynskhem Bok Swer; Ramesh Sharma
Journal:  Biogerontology       Date:  2020-09-23       Impact factor: 4.277

Review 5.  SATB family chromatin organizers as master regulators of tumor progression.

Authors:  Rutika Naik; Sanjeev Galande
Journal:  Oncogene       Date:  2018-11-09       Impact factor: 9.867

6.  Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.

Authors:  Diane K Birks; Andrew M Donson; Purvi R Patel; Alexandra Sufit; Elizabeth M Algar; Christopher Dunham; B K Kleinschmidt-DeMasters; Michael H Handler; Rajeev Vibhakar; Nicholas K Foreman
Journal:  Pediatr Blood Cancer       Date:  2013-02-04       Impact factor: 3.167

7.  Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets.

Authors:  Samantha Gadd; Simone Treiger Sredni; Chiang-Ching Huang; Elizabeth J Perlman
Journal:  Lab Invest       Date:  2010-03-08       Impact factor: 5.662

8.  RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer.

Authors:  Tokuhiro Chano; Kaichiro Ikebuchi; Yasuko Ochi; Hitosuke Tameno; Yasuhiko Tomita; Yufen Jin; Hideo Inaji; Makoto Ishitobi; Koji Teramoto; Ichiro Nishimura; Kahori Minami; Hirokazu Inoue; Takahiro Isono; Masao Saitoh; Taketoshi Shimada; Yasuo Hisa; Hidetoshi Okabe
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen.

Authors:  Velasco Cimica; Melissa E Smith; Zhikai Zhang; Deepti Mathur; Sridhar Mani; Ganjam V Kalpana
Journal:  BMC Cancer       Date:  2010-11-19       Impact factor: 4.430

10.  Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Authors:  Elizabeth M Algar; Andrea Muscat; Vinod Dagar; Christian Rickert; C W Chow; Jaclyn A Biegel; Paul G Ekert; Richard Saffery; Jeff Craig; Ricky W Johnstone; David M Ashley
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.